LONDON (Alliance News) - 4D Pharma PLC Wednesday said it has obtained regulatory and ethical approval for a phase 1 clinical trial in respect of Thetanix, its programme for the treatment of paediatric Crohn's disease, and release of the drug product ahead of the trial.
PCD is a chronic inflammatory bowel disease that causes inflammation, or swelling, across the lining of the digestive tract, often causing growth failure, malnutrition, pubertal delay and bone demineralisation.
4D said the phase 1 trial is expected to commence before the end of 2015.
"Obtaining regulatory and ethical approval and product release for the Thetanix trial are key milestones in the clinical trial process. We look forward to commencing the trial in line with our anticipated timeline, and assessing Thetanix and its effects in a clinical setting," Chief Scientific Officer Alex Stevenson said in a statement.
Shares in 4D Pharma were trading up 7.8% at 830.00 pence Wednesday morning.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
